TY - JOUR
T1 - Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation
AU - Amit, Guy
AU - Rosen, Amit
AU - Wagshal, Avraham B.
AU - Bonneh, Dan Y.
AU - Liss, Tzvika
AU - Grosbard, Aviva
AU - Ilia, Reuven
AU - Katz, Amos
PY - 2004/6/15
Y1 - 2004/6/15
N2 - The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.
AB - The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.
UR - http://www.scopus.com/inward/record.url?scp=2942580749&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2004.02.071
DO - 10.1016/j.amjcard.2004.02.071
M3 - Article
C2 - 15194037
AN - SCOPUS:2942580749
SN - 0002-9149
VL - 93
SP - 1558
EP - 1560
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 12
ER -